New obesity drug tested in 349 people – but not for weight loss yet
NCT ID NCT07313761
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This early-stage study tests how two different injection versions of the experimental drug AMG 133 are absorbed by the body in 349 adults with overweight or obesity. Participants receive a single dose, and researchers measure drug levels and safety. The goal is not to treat obesity but to gather data for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801-2658, United States
-
CenExel Collaborative Neuroscience Research, LLC Los Alamitos
Los Alamitos, California, 90720, United States
-
Clinical Pharmacology Of Miami, LLC
Miami, Florida, 33172-3161, United States
-
Ohio Clinical Trials, Inc.
Columbus, Ohio, 43212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?